Skip to content

Nurix Therapeutics

US · NRIX #2679 by market cap Listed 2020
12.85 -0.75 -5.51%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 6 in the most recent period (2026/Q3).
  • Total institutional ownership fell 6.8 percentage points.

Ownership vs. money flow

Diverging

Institutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
108.91% -6.84pp
Institutions
258 +6
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund50.87%
Hedge Fund32.58%
VC/PE Fund15.66%
Public Company7.73%
Private Company1.10%
Individual/Insider0.89%
Insurance Company0.47%
Government Pension Fund0.21%
Sovereign Wealth Fund0.17%

Top holders as of 2026-09-30

BlackRock 8.06% · 8.80M sh
Vestal Point Capital, LP 7.37% · 8.05M sh
Deep Track Capital, LP 7.08% · 7.74M sh
Rubric Capital Management LP 6.62% · 7.23M sh
Perceptive Advisors LLC 5.07% · 5.54M sh
T. Rowe Price Group, Inc. 4.98% · 5.44M sh
Morgan Stanley 4.80% · 5.25M sh
FMR 4.28% · 4.68M sh
Baker Bros. Advisors LP 4.26% · 4.66M sh
State Street Global Advisors 4.28% · 4.68M sh
Vanguard Capital Management, LLC 4.12% · 4.50M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 17 buys · 33 sells

NameRoleStake
Arthur Sands Chief Executive Officer 0.69%
Gwenn Hansen Chief Scientific Officer 0.11%
Johannes Van Houte Chief Financial Officer 0.04%
David Lacey Independent Director 0.03%
Julia Gregory Independent Chairperson 0.01%
Christine Ring Chief Legal Officer, Secretary & Chief Compliance Officer 0.00%
Judith Reinsdorf Independent Director --
Roy Baynes Independent Director --
Lori Kunkel Former Independent Director --
Paul Silva Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-03 Johannes Van Houte Chief Financial Officer Automatic Disposition -4,769 $15.38–16.20
2026-11-02 Christine Ring Chief Legal Officer, Secretary & Chief Compliance Officer Automatic Disposition -10,929 $25.74–26.76
2026-11-02 Christine Ring Chief Legal Officer, Secretary & Chief Compliance Officer Intent to Sell (Form 144) -6,113 $25.70
2026-11-01 Christine Ring Chief Legal Officer, Secretary & Chief Compliance Officer Derivative Exercise and Sale -5,786 $8.72–25.74
2026-11-01 Gwenn Hansen Chief Scientific Officer Derivative Exercise and Sale -1,452 $1.86–26.80
2026-10-29 Johannes Van Houte Chief Financial Officer Derivative Exercise and Sale -2,834 $26.28
2026-10-29 Johannes Van Houte Chief Financial Officer Derivative Exercise and Retained +7,348 --
2026-10-29 Christine Ring Chief Legal Officer, Secretary & Chief Compliance Officer Derivative Exercise and Sale -3,957 $26.28
2026-10-29 Christine Ring Chief Legal Officer, Secretary & Chief Compliance Officer Derivative Exercise and Retained +6,225 --
2026-10-29 Gwenn Hansen Chief Scientific Officer Open Market Disposition -3,957 $26.28
2026-10-29 Gwenn Hansen Chief Scientific Officer Derivative Exercise and Retained +10,182 --
2026-10-14 Gwenn Hansen Chief Scientific Officer Derivative Exercise and Sale -1,452 $1.86–25.00
2026-10-13 Julia Gregory Independent Chairperson Derivative Exercise and Sale -22,583 $1.86–23.40
2026-10-01 Christine Ring Chief Legal Officer, Secretary & Chief Compliance Officer Derivative Exercise and Sale -5,786 $8.72–23.19
2026-09-01 Christine Ring Chief Legal Officer, Secretary & Chief Compliance Officer Derivative Exercise and Sale -5,787 $8.72–26.64
2026-08-31 Gwenn Hansen Chief Scientific Officer Derivative Exercise and Sale -1,452 $1.86–25.47
2026-08-04 Gwenn Hansen Chief Scientific Officer Derivative Exercise and Sale -4,356 $1.86–25.00
2026-08-03 Johannes Van Houte Chief Financial Officer Automatic Disposition -4,761 $23.89–24.65
2026-08-03 Gwenn Hansen Chief Scientific Officer Automatic Disposition -4,111 $23.87–24.64
2026-08-02 Christine Ring Chief Legal Officer, Secretary & Chief Compliance Officer Automatic Disposition -10,802 $23.05

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Nurix Therapeutics discussion 0 comments

Add a comment